Jenex closes $305,100 placement



    BURLINGTON, ON, April 11 /CNW/ - The Jenex Corporation ("Jenex" or the
"Corporation") (TSX Venture Exchange - JEN) announces the Corporation has
closed its private placement previously announced on Stockwatch on March 13,
2007. Pursuant to this transaction, the Corporation has issued a total of
1,130,000 units at a price of $0.27 each for gross proceeds of $305,100. Each
unit consists of one common share and one half warrant. A whole warrant
entitles the holder to acquire, not later than April 10, 2008, one common
share for $0.40. In connection with the foregoing, the Corporation paid an
agent finder's fee to Kingsdale Capital Markets Inc. of $24,408 in cash and
56,500 warrants, on the same terms as the warrants issued to investors.
    The transaction has been given approval by the TSX Venture Exchange and
the shares and all underlying warrants will be subject to a four-month hold
period from the date of issue.
    Further to the press release on March 9, 2007, the TSX Venture Exchange,
has approved the issuance of 148,148 common shares at a deemed price of
27 cents per common share as consideration for the settlement of $40,000 in
trade payables owed to a consultant of the corporation. The proposed
transaction is arm's length. The shares will be subject to a four-month hold
period from the date of issue.

    About Kingsdale Capital

    Kingsdale Capital is a leading global financial services organization and
more information about Kingsdale can be found at www.kingsdalecapital.com.

    About The Jenex Corporation

    The Jenex Corporation owns a patented Thermal Therapy technology. The
first device developed from this technology is the Therapik(R) product, for
relief of pain and itch caused by insect stings and bites. Therapik(R) has
been approved as a Class II medical device in Canada (TPD) and the United
States (FDA), and has received CE approval in Europe. The second device,
interceptCS is the first product clinically proven and approved (TPD) to
prevent cold sores. interceptCS is available exclusively in Canada at Shoppers
Drug Mart/Pharmaprix. More information about the Corporation can be found at
www.JenexCorp.com & www.interceptCS.com.

    
                         "Prevention is the Solution"

           The TSX Venture Exchange Inc. has not reviewed and does
         not accept responsibility for the accuracy or the contents
                           of this press release.
    

    %SEDAR: 00016201E




For further information:

For further information: Direct Inquiries to: The Jenex Corporation, 207
- 940 Sheldon Court, Burlington, Ontario, L7L 5K6, Michael A. Jenkins,
Telephone: (905) 632-3830, Facsimile: (905) 632-3774, Email:
jenex@jenexcorp.com, Website: www.JenexCorp.com

Organization Profile

THE JENEX CORPORATION

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890